中国实用外科杂志2025，Vol.45Issue(10)：1177-1180,4.DOI:10.19538/j.cjps.issn1005-2208.2025.10.20
减重药物在青少年肥胖病人中应用进展
Advances in pharmacotherapy for adolescent obesity
摘要
Abstract
In recent years,weight-loss medications such as glucagon-like peptide-1 receptor agonist,and PHEN/TPM have brought breakthrough progress in the treatment of adolescent obesity.By targeting appetite control centers or inhibiting neurotransmitter re-uptake,they significantly improve clinical outcomes in obese adolescents.These drugs not only effectively reduce body weight but also ameliorate metabolic issues such as insulin resistance and dyslipidemia.However,their long-term safety,cost accessibility,and individualized medication strategies still require improvement.Moving forward,it is necessary to advance long-term follow-up studies and establish real-world databases to support personalized treatment.Medication therapy should be integrated with lifestyle interventions,building a"family-medical-society"tripartite management model to achieve precise prevention and management of adolescent obesity.关键词
青少年肥胖/减重药物/药物安全性/胰高血糖素样肽-1受体激动剂Key words
adolescent obesity/weight-loss pharmacothera-py/drug safety/glucagon-like peptide-1 receptor agonist分类
医药卫生引用本文复制引用
春万顺,汪和,胡梦杰,梅紫暄,王天爱,龚铖,潘定宇,李震..减重药物在青少年肥胖病人中应用进展[J].中国实用外科杂志,2025,45(10):1177-1180,4.基金项目
National Natural Science Foundation of Chi-na(No.82270612) （No.82270612）
Innovation Cultivation Fund of Zhongnan Hospital of Wuhan University(No.CXPY2022087) 国家自然科学基金项目(No.82270612) （No.CXPY2022087）
武汉大学中南医院创新培育基金项目(No.CXPY2022087) （No.CXPY2022087）
